• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Curis Inc. (Amendment)

    2/10/22 4:01:55 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRIS alert in real time by email
    SC 13G/A 1 r23220sc13ga1.htm AMENDMENT NO. 1

     

    CUSIP No. 231269200 Page 1 of 6

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     Amendment No. 1

     

    Under the Securities Exchange Act of 1934

     

     

    Curis, Inc.

    (Name of Issuer)

     

    Common Stock, Par Value $0.01 per share

    (Title of Class of Securities)

     

    231269200

    (CUSIP Number)

     

    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x       Rule 13d-1(b)

    o       Rule 13d-1(c)

    o       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

       
     

     

    CUSIP No. 231269200 Page 2 of 6

     

     

    1.

    Names of Reporting Person

     

    I.R.S. Identification Nos. of Above Persons (entities only)

     

    Sio Capital Management, LLC

     

    20-4586565

    2.

    Check the Appropriate Box

    if a Member of a Group

     

    (a) ¨

    (b) ¨

    3.

    SEC Use Only

     

     
    4.

    Citizenship or Place

    of Organization

     

    Delaware

    Number of Shares Beneficially

    Owned by Each Reporting

    Person With1

    5.

    Sole Voting Power

     

    -0-
    6.

    Shared Voting Power

     

    3,866,645

    7.

    Sole Dispositive Power

     

    -0-
    8.

    Shared Dispositive Power

     

    3,866,645

    9.

    Aggregate Amount Beneficially Owned by Each
    Reporting Person

     

    3,866,645

     

    10.

    Check Box if the Aggregate Amount in Row (9)
    Excludes Certain Shares

     

    ¨

    11.

    Percent of Class Represented by Amount in

    Row (9)

     

    4.22%2

     

    12.

    Type of Reporting Person

     

    IA

     

     

     

                                                                

    1 As of December 31, 2021, Sio Capital Management, LLC beneficially owned 3,866,645 shares of Common Stock with shared voting power and shared dispositive power. The ownership information reported in this Schedule 13G is as of December 31, 2021.

    2 Based on 91,609,165 shares of common stock outstanding as of November 2, 2021, as reported in the Issuer’s Form 10-Q filed with the SEC on November 9, 2021.

     

     

       
     

     

    CUSIP No. 231269200 Page 3 of 6

     

     

    Schedule 13G/A

     

    Item 1(a).Name of Issuer:

     

    Curis, Inc.

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    128 Spring Street, Building C - Suite 500,

    Lexington, Massachusetts 02421

     

    Item 2(a).Name of Persons Filing:

     

    This Statement is filed on behalf of Sio Capital Management, LLC (the “Reporting Person” or “Sio”)

     

    Sio is a registered investment adviser to certain affiliated funds that directly hold the shares of Common Stock to which this statement relates for the benefit of their respective investors, and in such capacity Sio has voting and dispositive power over such shares.

     

    Item 2(b).Address of Principal Business Office:

     

    600 Third Avenue, 2nd Floor

    New York, New York 10016

     

    Item 2(c).Citizenship:

     

    Sio is a Delaware limited liability company.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, Par Value $0.01 per share

     

     

    Item 2(e).CUSIP Number:

     

    231269200

     

       
     

     

    CUSIP No. 231269200 Page 4 of 6

     

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 73c).
    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C.78c).
    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) x An investment adviser in accordance with §13d-1(b)(1)(ii)(E).
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    ¨ If this statement is filed pursuant to §240.13d-1(c), check this box.

     

     

     

    Item 4. Ownership.

     

    (a) through (c):

     

    The information set forth in Items 5 through 9 and 11 of the cover pages to this Schedule 13G is incorporated herein by reference.3

     

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Various advisory clients of the Reporting Person have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock of Curis, Inc. in their accounts with the Reporting Person. No such person has such interest relating to more than 5% of the outstanding shares of Common Stock of Curis, Inc.

     

     

     

                                                                

    3 Sio and Sio GP, LLC (the “GP”) act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G. Because Sio’s investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.

     

       
     

     

    CUSIP No. 231269200 Page 5 of 6

     

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported By the Parent Holding Company.

     

    Not Applicable. 

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of a Group.

     

    Not Applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to herein were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

       
     

     

    CUSIP No. 231269200 Page 6 of 6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 8, 2022 

     

      SIO CAPITAL MANAGEMENT, LLC  
         
         
        By: /s/ Jin W. Lee  
        Name:  Jin W. Lee  
        Title: Chief Compliance Officer  

     

     

     

     

     

     

     

    Get the next $CRIS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRIS

    DatePrice TargetRatingAnalyst
    5/19/2025$17.00Buy
    H.C. Wainwright
    11/17/2023$26.00Buy
    Truist
    4/4/2022Outperform → Mkt Perform
    Raymond James
    10/13/2021$15.00Outperform
    Raymond James
    More analyst ratings

    $CRIS
    SEC Filings

    View All

    SEC Form PRE 14A filed by Curis Inc.

    PRE 14A - CURIS INC (0001108205) (Filer)

    2/9/26 4:55:02 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - CURIS INC (0001108205) (Filer)

    2/9/26 4:53:58 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - CURIS INC (0001108205) (Filer)

    1/7/26 7:50:58 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

    Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.

    1/9/26 8:00:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

    LEXINGTON, Mass., Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused, high-quality institutional investors and certain insiders of the Company for a private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses. The PIPE financing is expected to close on or abou

    1/7/26 8:45:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Provides Updated Data from its Frontline AML Triplet Study

    5 of 8 patients (62.5%) achieved Undetectable MRD (uMRD) LEXINGTON, Mass., Dec. 9, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, yesterday provided updated clinical data from the ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104) in a poster presentation at the 67th ASH Annual Meeting (ASH). The AML triplet study is evaluating the addition of emavusertib (ema) to the combination of venetoclax and azacitidine (ven-a

    12/9/25 8:00:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President & CEO Dentzer James E

    4 - CURIS INC (0001108205) (Issuer)

    5/22/25 4:13:54 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Hohneker John

    4 - CURIS INC (0001108205) (Issuer)

    5/22/25 4:13:41 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Greenacre Martyn D

    4 - CURIS INC (0001108205) (Issuer)

    5/22/25 4:13:30 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Curis with a new price target

    H.C. Wainwright resumed coverage of Curis with a rating of Buy and set a new price target of $17.00

    5/19/25 8:52:11 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist initiated coverage on Curis with a new price target

    Truist initiated coverage of Curis with a rating of Buy and set a new price target of $26.00

    11/17/23 7:37:50 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis downgraded by Raymond James

    Raymond James downgraded Curis from Outperform to Mkt Perform

    4/4/22 11:27:43 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Financials

    Live finance-specific insights

    View All

    Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025

    LEXINGTON, Mass., Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast

    10/30/25 4:00:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025

    LEXINGTON, Mass., July 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast c

    7/29/25 8:30:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

    LEXINGTON, Mass., April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can

    4/29/25 8:00:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Leadership Updates

    Live Leadership Updates

    View All

    Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations

    LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of three new executives to its management team. Joining the company, are Felix Geissler, M.D., Ph.D., as Vice President of Medical Affairs, Kimberly Steinmann, M.D., as Vice President of Clinical Development, and Dora Ferrari, as Vice President of Clinical Operations. They will be reporting directly to Dr. Reinhard von Roemeling, Senior Vice President, Clinical Devel

    1/3/22 8:00:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Appoints John A. Hohneker, M.D. To Board Of Directors

    LEXINGTON, Mass., Dec. 6, 2021  /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of John A. Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings 30 years of drug development and leadership experience within the biotech and pharmaceutical industries.  He most recently served as President and CEO of Anokion SA. Prior to Anokion, he was President of Research and Development at FORMA Therapeutics Inc., where he guided the company's transitio

    12/6/21 8:00:00 AM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., Jan. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 4, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 185,000 shares of Curis common stock to three new employees, with a grant date of January 4, 2021 (the "Q1 2021 Inducement Grants"). Each of the Q1 2021 Inducement Grants has an exercise price per share equal to the closing price of the Company's common stock on January 4, 2021. Each stock option has a 10 year term and vests ov

    1/8/21 4:01:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Curis Inc.

    SC 13G/A - CURIS INC (0001108205) (Subject)

    11/13/24 2:05:06 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Curis Inc.

    SC 13G - CURIS INC (0001108205) (Subject)

    11/1/24 4:35:37 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Curis Inc.

    SC 13G - CURIS INC (0001108205) (Subject)

    4/15/24 2:12:19 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care